Objective—To determine the refractive states of eyes in domestic cats and to evaluate correlations between refractive error and age, breed, and axial globe measurements.
Animals—98 healthy ophthalmologically normal domestic cats.
Procedures—The refractive state of 196 eyes (2 eyes/cat) was determined by use of streak retinoscopy. Cats were considered ametropic when the mean refractive state was ≥ ± 0.5 diopter (D). Amplitude-mode ultrasonography was used to determine axial globe length, anterior chamber length, and vitreous chamber depth.
Results—Mean ± SD refractive state of all eyes was −0.78 ± 1.37 D. Mean refractive error of cats changed significantly as a function of age. Mean refractive state of kittens (≤ 4 months old) was −2.45 ± 1.57 D, and mean refractive state of adult cats (> 1 year old) was −0.39 ± 0.85 D. Mean axial globe length, anterior chamber length, and vitreous chamber depth were 19.75 ± 1.59 mm, 4.66 ± 0.86 mm, and 7.92 ± 0.86 mm, respectively.
Conclusions and Clinical Relevance—Correlations were detected between age and breed and between age and refractive states of feline eyes. Mean refractive error changed significantly as a function of age, and kittens had greater negative refractive error than did adult cats. Domestic shorthair cats were significantly more likely to be myopic than were domestic mediumhair or domestic longhair cats. Domestic cats should be included in the animals in which myopia can be detected at a young age, with a likelihood of progression to emmetropia as cats mature.
Objective—To determine effects of the topically applied calcium-channel blocker flunarizine on intraocular pressure (IOP) in clinically normal dogs.
Procedures—Baseline diurnal IOPs were determined by use of a rebound tonometer on 2 consecutive days. Subsequently, 1 randomly chosen eye of each dog was treated topically twice daily for 5 days with 0.5% flunarizine. During this treatment period, diurnal IOPs were measured. In addition, pupillary diameter and mean arterial blood pressure (MAP) were evaluated. Serum flunarizine concentrations were measured on treatment day 5. Intraday fluctuation of IOP was analyzed by use of an ANOVA for repeated measures and a trend test. Changes in IOP from baseline values were assessed and compared with IOPs for the days of treatment. Values were also compared between treated and untreated eyes.
Results—A significant intraday fluctuation in baseline IOP was detected, which was highest in the morning (mean ± SE, 15.8 ± 0.63 mm Hg) and lowest at night (12.9 ± 0.61 mm Hg). After 2 days of treatment, there was a significant decrease in IOP from baseline values in treated (0.93 ± 0.35 mm Hg) and untreated (0.95 ± 0.34 mm Hg) eyes. There was no significant treatment effect on pupillary diameter or MAP. Flunarizine was detected in serum samples of all dogs (mean ± SD, 3.89 ± 6.36 μg/L).
Conclusions and Clinical Relevance—Topically applied flunarizine decreased IOP in dogs after 2 days of twice-daily application. This calcium-channel blocker could be effective in the treatment of dogs with glaucoma.